• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    The FDA Has Accepted Compass Pathways' Investigational New Drug Application for COMP360, Enabling the Initiation of a Late-Stage Clinical Trial in Post-traumatic Stress Disorder

    Benzinga·01/07/2026 11:33:03
    语音播报
    • FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trial
    • Compass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)